Newly Diagnosed with Multiple Myeloma: Understanding Your Condition & Next Steps

What Is Multiple Myeloma?

A plasma cell malignancy in the bone marrow. Clonal plasma cells produce monoclonal protein (M-protein), cause bone destruction, anemia, renal failure, immunosuppression. Second most common blood cancer (after NHL). Median age ~69.

CRAB Criteria (End-Organ Damage)

• Calcium elevation (>11 mg/dL or >1 mg/dL above ULN)
• Renal insufficiency (Cr >2 mg/dL or eGFR <40)
• Anemia (Hb >2 g/dL below LLN or <10 g/dL)
• Bone lesions (lytic on CT/PET-CT, MRI)

Plus: ≥60% clonal plasma cells, serum free light chain ratio ≥100, >1 focal lesion on MRI = SLiM criteria (myeloma-defining events).

Staging & Prognosis

• R-ISS (Revised International Staging System): Stage I–III by β2-microglobulin, albumin, LDH, cytogenetics (del17p, t(4;14), t(14;16)).
• High-risk cytogenetics: del(17p), t(4;14), t(14;16), gain 1q, p53 mut → shorter PFS/OS.
• Median OS: 8–10+ years (improving rapidly).

Diagnostic Workup

• SPEP/UPEP + immunofixation (M-spike, type)
• Serum free light chains (κ/λ ratio)
• Bone marrow biopsy (clonality, % plasma cells, FISH/cytogenetics)
• Imaging: Whole-body low-dose CT or PET-CT (preferred over skeletal survey)
• Labs: CBC, CMP, β2M, LDH, quantitative immunoglobulins

Treatment Algorithm (Transplant-Eligible vs. Ineligible)

Induction (4–6 cycles)

• Preferred: VRd (bortezomib/lenalidomide/dex) or DRd (daratumumab/len/dex) for transplant-eligible; DRd or VRd-lite for ineligible.
• Quadruplets (D-VRd, Isa-VRd) showing deeper responses in trials.

Consolidation

• High-dose melphalan + autologous stem cell transplant (ASCT) standard for eligible. Tandem transplant not routine.
• Ineligible: Continue induction or switch.

Maintenance

• Lenalidomide until progression (improves PFS/OS).
• Consider bortezomib addition for high-risk.

Relapsed/Refractory

• Mechanism-based: Switch proteasome inhibitor (carfilzomib, ixazomib), IMiD (pomalidomide), anti-CD38 (isatuximab), BCL2 (venetoclax if t(11;14)), bispecifics (teclistamab, talquetamab), CAR-T (ide-cel, cilta-cel).
• Clinical trials strongly encouraged at each relapse.

Supportive Care Essentials

• Bone: Zoledronic acid/denosumab q4wks → q12wks + dental monitoring.
• Infection: IVIG if IgG <400 + recurrent infections; prophylaxis (antivirals, PJP).
• Renal: Hydration, avoid NSAIDs, manage hypercalcemia.
• Neuropathy: Dose-adjust bortezomib; subQ preferred; gabapentin/duloxetine.
• VTE prophylaxis: Aspirin or anticoagulant with IMiDs.

Living Well

• Exercise (resistance + aerobic) preserves muscle/bone.
• Nutrition: Adequate protein, calcium, vitamin D.
• Psychosocial: Support groups (IMF, MMRF), counseling, financial navigation.
• Shared decision-making at every transition.

Key Message

Multiple myeloma is a chronic, manageable disease for most. Rapid therapeutic advances (quadruplets, bispecifics, CAR-T) are deepening responses and extending survival. Partner with a myeloma specialist.